How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
Kåre Inge BirkelandJohan BodegardAnna NorhammarJosephina G KuiperElena GeorgiadoWendy L Beekman-HendriksMarcus ThuressonMarc PignotRon M C HeringsAdriaan KooyPublished in: Diabetes, obesity & metabolism (2019)
In large T2D populations within Europe, consistent patterns of representativeness of CVOTs were found when applying the main enrolment criteria. The DECLARE-TMI 58 trial had the highest representativeness, indicating that it included and examined patients who are most representative of the general T2D patients in the studied countries.